Patent intelligence · US
US 9694071
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
Patent details — US 9694071
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 4, 2017
- Expiration
- Jun 29, 2037
- Applicant
- TG Therapeutics, Inc.
- Claims
- 25
- CPC classes
- A61K, A61K31/519, A61K39/3955, A61K45/06
Quick answer
US 9694071 (Combination of anti-CD20 antibody and PI3 kinase selective inhibitor) is held by TG Therapeutics, Inc.. Status: granted. Granted Jul 4, 2017. Expires Jun 29, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TG Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/519, A61K39/3955, A61K45/06, A61P, A61P37/00
More from TG Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11965032
Anti-CD20 antibody compositions
granted -
US 11884740
Anti-CD20 antibody compositions
granted -
US 11814439
Anti-CD20 antibody compositions
granted -
US 11807689
Anti-CD20 antibody compositions
granted -
US 10966977
Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
granted -
US 10729768
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
granted
Frequently asked questions
What is US patent 9694071?
US 9694071 (Combination of anti-CD20 antibody and PI3 kinase selective inhibitor) is held by TG Therapeutics, Inc.. Status: granted. Granted Jul 4, 2017. Expires Jun 29, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9694071?
TG Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 9694071 expire?
Our index shows an expiration date of Jun 29, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.